Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3-D optical coherence tomography analysis.
OCT
acetylsalicylic acid
cardiac allograft vasculopathy
lipid plaque
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
10
02
2024
received:
08
11
2023
accepted:
16
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
ppublish
Résumé
There is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV). A nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors. In total, 175 patients (mean age 52 ± 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699) CONCLUSION: This study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.
Sections du résumé
BACKGROUND
BACKGROUND
There is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV).
METHODS
METHODS
A nationwide prospective two-center study investigated changes in the coronary artery vasculature by highly automated 3-D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on coronary artery microvascular changes was analyzed in the overall study cohort and after propensity score matching for selected clinical CAV risk factors.
RESULTS
RESULTS
In total, 175 patients (mean age 52 ± 12 years, 79% male) were recruited. During the 1-year follow-up, both intimal and media thickness progressed, with ASA having no effect on its progression. However, detailed OCT analysis revealed that ASA use was associated with a lower increase in lipid plaque (LP) burden (p = .013), while it did not affect the other observed pathologies. Propensity score matching of 120 patients (60 patient pairs) showed similar results, with ASA use associated with lower progression of LPs (p = .002), while having no impact on layered fibrotic plaque (p = .224), calcification (p = .231), macrophage infiltration (p = .197), or the absolute coronary artery risk score (p = .277). According to Kaplan-Meier analysis, ASA use was not associated with a significant difference in survival (p = .699) CONCLUSION: This study showed a benefit of early ASA use after HTx on LP progression. However, ASA use did not have any impact on the progression of other OCT-observed pathologies or long-term survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15275Subventions
Organisme : NIH HHS
ID : R01-EB004640
Pays : United States
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart And Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38:1056-1066. doi:10.1016/j.healun.2019.08.004
Hsich E, Singh TP, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart And Lung Transplantation: thirty-ninth adult heart transplantation report-2022; focus on transplant for restrictive heart disease. J Heart Lung Transplant. 2022;41:1366-1375. doi:10.1016/j.healun.2022.07.018
Chih S, Chong AY, Mielniczuk LM, et al. Allograft vasculopathy: the achilles’ heel of heart transplantation. J Am Coll Cardiol. 2016;68:80-91. doi:10.1016/j.jacc.2016.04.033
Matsuo Y, Cassar A, Li J, et al. Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy. Eur Heart J. 2013;34:2905-2915. doi:10.1093/eurheartj/eht209
Kim M, Bergmark BA, Zelniker TA, et al. Early aspirin use and the development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2017;36:1344-1349. doi:10.1016/j.healun.2017.06.015
Peled Y, Lavee J, Raichlin E, et al. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clin Transplant. 2017;31:e13133. doi:10.1111/ctr.13133
Costanzo MR, Dipchand A, Starling R, et al. The International society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914-956. doi:10.1016/j.healun.2010.05.034
Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015
Pazdernik M, Chen Z, Bedanova H, et al. Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis. J Heart Lung Transplant. 2018;37:992-1000. doi:10.1016/j.healun.2018.04.002
Chen Z, Pazdernik M, Zhang H, et al. Quantitative 3D analysis of coronary wall morphology in heart transplant patients: OCT-assessed cardiac allograft vasculopathy progression. Med Image Anal. 2018;50:95-105. doi:10.1016/j.media.2018.09.043
Jensen NM, Chen Z, Clemmensen TS, et al. Validation of a semi-automatic software for optical coherence tomography-analysis in heart transplanted patients. Int J Cardiovasc Imaging. 2023;39:257-268. doi:10.1007/s10554-022-02722-9
Pazdernik M, Bedanova H, Chen Z, et al. Donor specific anti-HLA antibodies and cardiac allograft vasculopathy: a prospective study using highly automated 3-D optical coherence tomography analysis. Transpl Immunol. 2021;65:101340. doi:10.1016/j.trim.2020.101340
Potena L, Holweg CTJ, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398-405. doi:10.1097/01.tp.0000229039.87735.76
Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96:1398-1402. doi:10.1161/01.cir.96.5.1398
Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med. 1995;333:621-627. doi:10.1056/NEJM199509073331003
Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Eng J Med. 2003;349:847-858. doi:10.1056/NEJMoa022171
Clemmensen TS, Holm NR, Eiskjaer H, et al. Detection of early changes in the coronary artery microstructure after heart transplantation: a prospective optical coherence tomography study. J Heart Lung Transplant. 2018;37:486-495. doi:10.1016/j.healun.2017.10.014
Cassar A, Matsuo Y, Herrmann J, et al. Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. Eur Heart J. 2013;34:2610-2617. doi:10.1093/eurheartj/eht236
Oberkofler CE, Raptis DA, Müller PC, et al. Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation. Liver Transpl. 2022;28(12):1888-1898. doi:10.1002/lt.26534. Epub 2022 Aug 5
Zhang X, Chang A, Zou Y, et al. Aspirin attenuates cardiac allograft rejection by inhibiting the maturation of dendritic cells via the NF-κB signaling pathway. Front Pharmacol. 2021;12:706748. doi:10.3389/fphar.2021.706748
McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol. 1995;147:293-308.
Bjerre KP, Clemmensen TS, Berg K, et al. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy. J Heart Lung Transplant. 2020;39:371-378. doi:10.1016/j.healun.2020.01.1344
Asleh R, Briasoulis A, Smith B, et al. Association of aspirin treatment with cardiac allograft vasculopathy progression and adverse outcomes after heart transplantation. J Card Fail. 2021;27:542-551. doi:10.1016/j.cardfail.2021.01.019
Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801-815. doi:10.1161/01.RES.0000246086.93555.f3
Clemmensen TS, Holm NR, Eiskjaer H, et al. Layered fibrotic plaques are the predominant component in cardiac allograft vasculopathy: systematic findings and risk stratification by OCT. JACC Cardiovasc Imaging. 2017;10:773-784. doi:10.1016/j.jcmg.2016.10.021
Cyrus T, Sung S, Zhao L. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1282-1287. doi:10.1161/01.cir.0000027816.54430.96
Nishimura S, Ehara S, Hasegawa T, et al. Cholesterol crystal as a new feature of coronary vulnerable plaques: an optical coherence tomography study. J Cardiol. 2017;69:253-259. doi:10.1016/j.jjcc.2016.04.003
Fry L, Lee A, Khan S, et al. Effect of aspirin on cholesterol crystallization: a potential mechanism for plaque stabilization. Am Heart J Plus Cardiol Res Pract. 2022;13:100083. doi:10.1016/j.ahjo.2021.100083
Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. 2010;464:1357-1361. doi:10.1038/nature08938
Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events-a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006;28:1-10. doi:10.1002/sca.4950280101